Shares of Inhibrx Biosciences rose Monday after the company announced positive preliminary results from its trial of a new head-and-neck cancer treatment. The drug, INBRX-106, showed positive results ...
Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab versus pembrolizumab as first-line treatment for PD-L1 positive advanced non-small cell lung cancer (NSCLC): Results from the randomized, ...
Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with resectable locally advanced head and neck squamous ...
The FDA approved a subcutaneous formulation of the blockbuster cancer drug pembrolizumab (Keytruda Qlex) for use across the drug's numerous solid tumors indications. The new formulation combines ...
A 'lifeline' one-minute cancer injection is being rolled out to tens of thousands of patients on the NHS - the new pembrolizumab jab will save hours spent in immunotherapy ...
The PD-1 inhibitor pembrolizumab, a cancer immunotherapy drug, shrank or halted growth of tumors in 76 percent of patients with pleural mesothelioma, a rare and deadly form of cancer that arises in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results